164 related articles for article (PubMed ID: 30952593)
1. Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.
Radakovic A; Boger DL
Bioorg Med Chem Lett; 2019 Jun; 29(11):1370-1374. PubMed ID: 30952593
[TBL] [Abstract][Full Text] [Related]
2. High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.
Radakovic A; Boger DL
Bioorg Med Chem Lett; 2018 Mar; 28(5):863-865. PubMed ID: 29439899
[TBL] [Abstract][Full Text] [Related]
3. A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.
Leggans EK; Duncan KK; Barker TJ; Schleicher KD; Boger DL
J Med Chem; 2013 Feb; 56(3):628-39. PubMed ID: 23244701
[TBL] [Abstract][Full Text] [Related]
4. Ultrapotent vinblastines in which added molecular complexity further disrupts the target tubulin dimer-dimer interface.
Carney DW; Lukesh JC; Brody DM; Brütsch MM; Boger DL
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9691-8. PubMed ID: 27512044
[TBL] [Abstract][Full Text] [Related]
5. New prospects for vinblastine analogues as anticancer agents.
Silvestri R
J Med Chem; 2013 Feb; 56(3):625-7. PubMed ID: 23316748
[TBL] [Abstract][Full Text] [Related]
6. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.
Dumontet C; Jaffrezou JP; Tsuchiya E; Duran GE; Chen KG; Derry WB; Wilson L; Jordan MA; Sikic BI
Bull Cancer; 2004 May; 91(5):E81-112. PubMed ID: 15568225
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
8. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.
Mohan L; Raghav D; Ashraf SM; Sebastian J; Rathinasamy K
Biomed Pharmacother; 2018 Sep; 105():506-517. PubMed ID: 29883946
[TBL] [Abstract][Full Text] [Related]
9. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.
Okouneva T; Hill BT; Wilson L; Jordan MA
Mol Cancer Ther; 2003 May; 2(5):427-36. PubMed ID: 12748304
[TBL] [Abstract][Full Text] [Related]
10. Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.
Allemann O; Cross RM; Brütsch MM; Radakovic A; Boger DL
Bioorg Med Chem Lett; 2017 Jul; 27(14):3055-3059. PubMed ID: 28551101
[TBL] [Abstract][Full Text] [Related]
11. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
12. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
13. New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies.
Orosz F; Comin B; Raïs B; Puigjaner J; Kovács J; Tárkányi G; Acs T; Keve T; Cascante M; Ovádi J
Br J Cancer; 1999 Mar; 79(9-10):1356-65. PubMed ID: 10188876
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of vinca alkaloid analogues.
Voss ME; Ralph JM; Xie D; Manning DD; Chen X; Frank AJ; Leyhane AJ; Liu L; Stevens JM; Budde C; Surman MD; Friedrich T; Peace D; Scott IL; Wolf M; Johnson R
Bioorg Med Chem Lett; 2009 Feb; 19(4):1245-9. PubMed ID: 19147348
[TBL] [Abstract][Full Text] [Related]
15. Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel.
Ashraf SM; Sebastian J; Rathinasamy K
Cell Prolif; 2019 Mar; 52(2):e12558. PubMed ID: 30525278
[TBL] [Abstract][Full Text] [Related]
16. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
17. Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.
Lukesh JC; Carney DW; Dong H; Cross RM; Shukla V; Duncan KK; Yang S; Brody DM; Brütsch MM; Radakovic A; Boger DL
J Med Chem; 2017 Sep; 60(17):7591-7604. PubMed ID: 28857558
[TBL] [Abstract][Full Text] [Related]
18. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations.
Jordan MA; Wilson L
Biochemistry; 1990 Mar; 29(11):2730-9. PubMed ID: 2346745
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
Jordan MA; Himes RH; Wilson L
Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
